HK Stock Movement | QYUNS-B (02509) Surges Over 7% After Repurchasing HKD 18M+ This Month; QX027N Gains Two Clinical Trial Approvals

Stock News

Nov 27

QYUNS-B (02509) rose over 7% in early trading, settling at a 4.97% gain to HKD 21.98 by press time, with a turnover of HKD 8.5648 million. The company announced on November 25 that it repurchased 23,000 shares for HKD 473,000. Data shows continuous share buybacks this month, totaling 901,800 shares acquired at a cumulative cost of HKD 18.2407 million. Additionally, QYUNS-B recently disclosed that its self-developed long-acting bispecific antibody QX027N injection received two implied clinical trial approvals from China's National Medical Products Administration Center for Drug Evaluation. The drug is intended for treating asthma and atopic dermatitis. This milestone marks the company's entry into the clinical stage for its innovative bispecific antibody pipeline in autoimmune and allergic diseases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1173683741"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173683741\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173683741?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 11:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173683741","market":"hk","top_or_hot":-1,"title":"HK Stock Movement | QYUNS-B (02509) Surges Over 7% After Repurchasing HKD 18M+ This Month; QX027N Gains Two Clinical Trial Approvals","media":"Stock News","content":"<p>QYUNS-B (02509) rose over 7% in early trading, settling at a 4.97% gain to HKD 21.98 by press time, with a turnover of HKD 8.5648 million. The company announced on November 25 that it repurchased 23,000 shares for HKD 473,000. Data shows continuous share buybacks this month, totaling 901,800 shares acquired at a cumulative cost of HKD 18.2407 million. Additionally, QYUNS-B recently disclosed that its self-developed long-acting bispecific antibody QX027N injection received two implied clinical trial approvals from China's National Medical Products Administration Center for Drug Evaluation. The drug is intended for treating asthma and atopic dermatitis. This milestone marks the company's entry into the clinical stage for its innovative bispecific antibody pipeline in autoimmune and allergic diseases.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | QYUNS-B (02509) Surges Over 7% After Repurchasing HKD 18M+ This Month; QX027N Gains Two Clinical Trial Approvals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | QYUNS-B (02509) Surges Over 7% After Repurchasing HKD 18M+ This Month; QX027N Gains Two Clinical Trial Approvals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-27 11:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>QYUNS-B (02509) rose over 7% in early trading, settling at a 4.97% gain to HKD 21.98 by press time, with a turnover of HKD 8.5648 million. The company announced on November 25 that it repurchased 23,000 shares for HKD 473,000. Data shows continuous share buybacks this month, totaling 901,800 shares acquired at a cumulative cost of HKD 18.2407 million. Additionally, QYUNS-B recently disclosed that its self-developed long-acting bispecific antibody QX027N injection received two implied clinical trial approvals from China's National Medical Products Administration Center for Drug Evaluation. The drug is intended for treating asthma and atopic dermatitis. This milestone marks the company's entry into the clinical stage for its innovative bispecific antibody pipeline in autoimmune and allergic diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1173683741","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173683741","pubTimestamp":1764213495,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"QYUNS-B (02509) rose over 7% in early trading, settling at a 4.97% gain to HKD 21.98 by press time, with a turnover of HKD 8.5648 million. The company announced on November 25 that it repurchased...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02509":"荃信生物-B"},"translate_title":"港股动向|QYUNS-B(02509)本月回购逾1800万港元后急升超7%；QX027N获得两项临床试验批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"QYUNS-B (02509) rose over 7% in early trading, settling at a 4.97% gain to HKD 21.98 by press time, with a turnover of HKD 8.5648 million. The company announced on November 25 that it repurchased 23,000 shares for HKD 473,000. Data shows continuous share buybacks this month, totaling 901,800 shares acquired at a cumulative cost of HKD 18.2407 million. Additionally, QYUNS-B recently disclosed that its self-developed long-acting bispecific antibody QX027N injection received two implied clinical trial approvals from China's National Medical Products Administration Center for Drug Evaluation. The drug is intended for treating asthma and atopic dermatitis. This milestone marks the company's entry into the clinical stage for its innovative bispecific antibody pipeline in autoimmune and allergic diseases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}